Find Individuals That Inspire You Find Individuals That Inspire You
Eric Jonasch, MD, reflects on the impact that his mentor had on his philosophy and approach to the treatment of patients with renal cell carcinoma.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 21, 2022 Category: Consumer Health News Tags: Hematology-Oncology MDAngle Source Type: news

SABR With Pembrolizumab Benefits Oligometastatic Kidney Cancer SABR With Pembrolizumab Benefits Oligometastatic Kidney Cancer
The combination of stereotactic ablative body radiotherapy and a short-course of pembrolizumab is well tolerated and provides excellent local control of oligometastatic renal-cell carcinoma.Reuters Health Information (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - December 30, 2021 Category: Radiology Tags: Hematology-Oncology News Source Type: news

Allarity Therapeutics Submits New Drug Application (NDA) to the U.S. FDA for Dovitinib for Third-Line Treatment of Renal Cell Carcinoma (RCC)
Marks Allarity’s first regulatory application for marketing approval for one of its prioritized oncology pipeline programs NDA is supported by Allarity’s previously-filed pre-market approval (PMA) submission to the FDA for the... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - December 22, 2021 Category: Drugs & Pharmacology Source Type: news

Novel Agent May Be Game-Changer in Rare Genetic Disease Novel Agent May Be Game-Changer in Rare Genetic Disease
Patients with von Hippel-Lindau face a high risk of renal cell carcinoma and other cancers, which often require multiple surgeries. A new drug may change the course of the disease.Medscape Medical News (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - December 1, 2021 Category: Intensive Care Tags: Hematology-Oncology News Source Type: news

FDA Nod for Adjuvant Pembrolizumab in Kidney Cancer FDA Nod for Adjuvant Pembrolizumab in Kidney Cancer
This is the first immunotherapy to be approved for adjuvant use in intermediate- or high-risk patients with renal cell carcinoma after surgery.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 18, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

FDA Approves Merck ’s Keytruda (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Surgery
Keytruda Is Now Approved for the Adjuvant Treatment of Patients With RCC at Intermediate-High or High Risk of Recurrence Following Nephrectomy, or Following Nephrectomy and Resection of Metastatic Lesions Keytruda Is the First Immunotherapy... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 18, 2021 Category: Drugs & Pharmacology Source Type: news

FDA approves pembrolizumab for adjuvant treatment of renal cell carcinoma
On November 17, 2021, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) for the adjuvant treatment of patients with renal cell carcinoma (RCC) at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - November 17, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

What Is the Most Common Type of Renal Cell Carcinoma?
Title: What Is the Most Common Type of Renal Cell Carcinoma?Category: Diseases and ConditionsCreated: 11/5/2021 12:00:00 AMLast Editorial Review: 11/5/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - November 5, 2021 Category: Cancer & Oncology Source Type: news

What Is Life Expectancy of Renal Cell Carcinoma
What Is the Life Expectancy of Someone with Renal Cell Carcinoma? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - October 27, 2021 Category: General Medicine Source Type: news

Kidney cancer: Two symptoms located on the back warning of the common cancer
KIDNEY cancer, or renal cell cancer, is one of the most common types of cancers in the UK. It usually affects adults in their 60s or 70s. (Source: Daily Express - Health)
Source: Daily Express - Health - October 22, 2021 Category: Consumer Health News Source Type: news

Renal Cell Carcinoma Highlights From ESMO 2021 Renal Cell Carcinoma Highlights From ESMO 2021
Dr Brian Rini, of Vanderbilt University, discusses key RCC abstracts from ESMO 2021, including data on efficacy and quality-of-life endpoints from the STAR, PRISM, and KEYNOTE-564 trials.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 12, 2021 Category: Consumer Health News Tags: None ReCAP Source Type: news

New Opdivo/Yervoy Mesothelioma Clinical Trial Begins Soon
A novel clinical trial involving the immunotherapy combination of Opdivo and Yervoy will open soon in Chicago. The goal is to study the drugs’ efficacy when added to surgery for patients with peritoneal mesothelioma cancer. The single-center, phase II clinical trial follows a recent report detailing the impressive three-year effectiveness of the drug combination when used for unresectable pleural mesothelioma. Bristol Myers Squibb manufactures Opdivo and Yervoy, known generically as nivolumab and ipilimumab. The U.S. Food and Drug Administration approved the combination for pleural mesothelioma in 2020, making ...
Source: Asbestos and Mesothelioma News - October 7, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Adjuvant Pembrolizumab Beneficial in Renal Cell Carcinoma
Rate of disease - free survival at 24 months higher with pembrolizumab versus placebo following nephrectomy (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - August 19, 2021 Category: Cancer & Oncology Tags: Nephrology, Oncology, Pharmacy, Journal, Source Type: news

Adjuvant Pembrolizumab Beneficial in Renal Cell Carcinoma
THURSDAY, Aug. 19, 2021 -- For patients with clear-cell renal cell carcinoma at high risk for recurrence after nephrectomy, adjuvant therapy with pembrolizumab improves disease-free survival, according to a study published in the Aug. 19 issue of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 19, 2021 Category: Pharmaceuticals Source Type: news

' Dawn of a New Era' in the Treatment of Renal Cell Carcinoma'Dawn of a New Era' in the Treatment of Renal Cell Carcinoma
Adjuvant pembrolizumab demonstrates significant disease-free survival benefit without excess toxicity in patients at high risk of recurrence.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 18, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

FDA OKs Belzutifan for Cancers Tied to von Hippel-Lindau Disease FDA OKs Belzutifan for Cancers Tied to von Hippel-Lindau Disease
The new drug is for patients with von Hippel-Lindau disease who require therapy for a number of associated cancers, including renal cell carcinoma.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 13, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

FDA approves lenvatinib plus pembrolizumab for advanced renal cell carcinoma
(Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - August 11, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA Approves Keytruda (pembrolizumab) Plus Lenvima (lenvatinib) Combination for First-Line Treatment of Adult Patients With Advanced Renal Cell Carcinoma (RCC)
August 11, 2021 Keytruda Plus Lenvima Is Now Approved for Two Types of Cancer, Including Advanced RCC Based on Phase 3 CLEAR/KEYNOTE-581 Trial, Keytruda Plus Lenvima Significantly Reduced Risk of Disease Progression or Death by 61% Versus... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 11, 2021 Category: Drugs & Pharmacology Source Type: news

Second- and Later-Line Treatment of Metastatic RCC Second- and Later-Line Treatment of Metastatic RCC
When first-line treatments for metastatic renal cell carcinoma fail, what are the next options?Current Opinion in Urology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 19, 2021 Category: Consumer Health News Tags: Urology Journal Article Source Type: news

Urine Test Differentiates Kidney Cancer From Benign Lesions Urine Test Differentiates Kidney Cancer From Benign Lesions
For patients with kidney lesions, urine tests under development can differentiate renal cell cancer from benign masses, say investigators.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 16, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

FDA approves nivolumab plus cabozantinib for advanced renal cell carcinoma
Hematology / Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 11, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

ASCO: Pembrolizumab Ups DFS in High-Risk Resected Clear-Cell RCC
FRIDAY, June 4, 2021 -- For patients with fully resected intermediate-high-risk or high-risk clear-cell renal cell carcinoma (ccRCC), adjuvant therapy with pembrolizumab yields a significant and clinically meaningful improvement in disease-free... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 4, 2021 Category: Pharmaceuticals Source Type: news

Dana-Farber researchers present key studies at ASCO annual meeting
(Dana-Farber Cancer Institute) Dana-Farber Cancer Institute researchers are presenting at the 2021 Annual Meeting of the American Society of Clinical Oncology (ASCO). Toni K. Choueiri, MD, will present results from the randomized, double-blind, phase III KEYNOTE-564 trial evaluating pembrolizumab versus placebo after surgery in patients with renal cell carcinoma during ASCO's Plenary Session. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 20, 2021 Category: Cancer & Oncology Source Type: news

Occult Brain Mets Detected in Patients With Advanced Renal Cancer
MONDAY, May 3, 2021 -- Occult brain metastasis is identified in about 4 percent of patients with metastatic renal cell carcinoma (mRCC), according to a study published in the April issue of the Journal of the National Comprehensive Cancer... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 3, 2021 Category: Pharmaceuticals Source Type: news

Metastatic renal-cell carcinoma treated with first-line monotherapy: considerable burden, high unmet needs
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - April 30, 2021 Category: Drugs & Pharmacology Source Type: news

FDA D.I.S.C.O. Burst Edition: FDA approval of Fotivda (tivozanib) for adult patients with relapsed or refractory advanced renal cell carcinoma following two or more prior systemic therapies
Listen to a soundcast of the March 10, 2021 FDA approval of Fotivda (tivozanib) for adult patients with relapsed or refractory advanced renal cell carcinoma following two or more prior systemic therapies. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - April 9, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Obesity Tied to Increased Mortality Overall in Patients With Cancer
Risk for death lower for patients with lung cancer, renal cell carcinoma, melanoma with versus without obesity (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - March 30, 2021 Category: Cancer & Oncology Tags: Dermatology, Gastroenterology, Gynecology, Internal Medicine, Nephrology, Oncology, Pathology, Pulmonology, Radiology, Journal, Source Type: news

High BMI Tied to Better Overall Survival in Immune Checkpoint Inhibitor-Treated Metastatic RCC High BMI Tied to Better Overall Survival in Immune Checkpoint Inhibitor-Treated Metastatic RCC
In patients with metastatic renal cell carcinoma treated with PD-1/PD-L1-based immune checkpoint inhibitors (ICIs), higher body mass index was associated with improved overall survival in a database study.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 15, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

FOTIVDA (tivozanib), FDA Approved for Treatment of Relapsed/Refractory Advanced Renal Cell Carcinoma, Available at Biologics by McKesson
CARY, N.C., March 12, 2021 —Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected by AVEO Oncology as a specialty pharmacy provider for FOTIVDA® (tivozanib) for the treatment of adult patients with relapsed or refractory advanced renal ... (Source: McKesson News)
Source: McKesson News - March 12, 2021 Category: Information Technology Source Type: news

Aveo finally earns approval for kidney cancer drug
More than 14 years after Boston-based Aveo Oncology licensed an experimental cancer drug from a Japanese biotech, the company announced Wednesday that the drug has earned approval by the U.S. Food and Drug Administration to treat kidney cancer, ending a long and tumultuous journey. The pill has the generic name of tivozanib, and will be marketed under the brand name, Fotivda, for use by patients with relapsed or refractory advanced renal cell carcinoma who have tried at least two other drugs previously. The… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - March 10, 2021 Category: Pharmaceuticals Authors: Don Seiffert Source Type: news

Aveo finally earns approval for kidney cancer drug
More than 14 years after Boston-based Aveo Oncology licensed an experimental cancer drug from a Japanese biotech, the company announced Wednesday that the drug has earned approval by the U.S. Food and Drug Administration to treat kidney cancer, ending a long and tumultuous journey. The pill has the generic name of tivozanib, and will be marketed under the brand name, Fotivda, for use by patients with relapsed or refractory advanced renal cell carcinoma who have tried at least two other drugs previously. The… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - March 10, 2021 Category: Biotechnology Authors: Don Seiffert Source Type: news

FDA approves tivozanib for relapsed or refractory advanced renal cell carcinoma
Hematology / Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 10, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA Approves Fotivda (tivozanib) for the Treatment of Adult Patients with Relapsed or Refractory Advanced Renal Cell Carcinoma
BOSTON--(BUSINESS WIRE) March 10, 2021 -- AVEO Oncology (Nasdaq: AVEO) today announced that the U.S. Food and Drug Administration (FDA) has approved Fotivda (tivozanib) for the treatment of adults with relapsed or refractory advanced renal cell... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 10, 2021 Category: Drugs & Pharmacology Source Type: news

New hope for advanced kidney cancer patients
Renal cell carcinoma, the most common form of kidney cancer, can quickly spread through the body and if diagnosed at a late stage it is usually inoperable, with patients given only a year to live. (Source: the Mail online | Health)
Source: the Mail online | Health - March 6, 2021 Category: Consumer Health News Source Type: news

Nivolumab Plus Cabozantinib Tops Sunitinib for Renal Cell Carcinoma
WEDNESDAY, March 3, 2021 -- For patients with previously untreated advanced renal cell carcinoma, nivolumab plus cabozantinib has significant benefits over sunitinib with respect to progression-free and overall survival, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 3, 2021 Category: Pharmaceuticals Source Type: news

Oncotarget: Identification intermediate-risk subgroups in metastatic clear-cell renal cell carcinoma
(Impact Journals LLC) " Elevated PLT count seems to identify a subgroup of patients with poor outcome in the IMDC intermediate-risk population with ccRCC " (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 1, 2021 Category: Cancer & Oncology Source Type: news

Cabozantinib may be cost effective in advanced renal cell carcinoma
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - March 1, 2021 Category: Drugs & Pharmacology Source Type: news

FDA D.I.S.C.O. Burst Edition: Enhertu (fam-trastuzumab deruxtecan-nxki ) and combination of Opdivo (nivolumab) and Cabometyx (cabozantinib)
Enhertu (fam-trastuzumab deruxtecan-nxki) for locally advanced or metastatic HER2-positive gastric or gastroesophageal adenocarcinoma and received a prior trastuzumab-based regimen. Combination of Opdivo (nivolumab) + Cabometyx (cabozantinib) as first-line treatment for advanced renal cell carcinoma (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 25, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

CT-guided renal ablation is safe for treating cancer in obese patients
CT-guided renal ablation is a safe and effective alternative to nephrectom...Read more on AuntMinnie.comRelated Reading: AI could help radiologists better detect kidney cancer Cryoablation comparable to surgery for kidney cancer Do more CT scans lead to more kidney surgeries? SPECT/CT can solve renal cell carcinoma diagnosis conundrum (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - February 24, 2021 Category: Radiology Source Type: news

Lenvatinib Plus Pembrolizumab Tops Sunitinib in Advanced RCC
FRIDAY, Feb. 19, 2021 -- For first-line treatment of advanced renal cell carcinoma, progression-free and overall survival are significantly longer with lenvatinib plus pembrolizumab versus sunitinib, according to a study published online Feb. 13 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 19, 2021 Category: Pharmaceuticals Source Type: news

Combo Shows'Impressive' Survival Results in First-Line RCC Combo Shows'Impressive' Survival Results in First-Line RCC
The combination of lenvatinib and pembrolizumab outperformed sunitinib as first-line therapy for advanced clear-cell renal cell carcinoma (RCC) in the CLEAR trial.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 18, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Cabozantinib Prolongs PFS in Papillary Renal Cell Carcinoma
WEDNESDAY, Feb. 17, 2021 -- For adults with papillary renal cell carcinoma (PRCC), the dual vascular endothelial growth factor (VEGF)-MET (hepatocyte growth factor receptor) inhibitor cabozantinib improves progression-free survival (PFS), according... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 17, 2021 Category: Pharmaceuticals Source Type: news

Cabozantinib Could Be New Standard for Papillary RCC Cabozantinib Could Be New Standard for Papillary RCC
Cabozantinib outperforms the current standard of care for renal cell carcinoma (RCC), according to results from the Southwest Oncology Group 1500 trial.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 17, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Which Patients With Kidney Cancer Are Likely to Respond to ICI? Which Patients With Kidney Cancer Are Likely to Respond to ICI?
Several factors in patients with clear cell renal cell carcinoma are associated with a diminished response to immune checkpoint inhibition (ICI).Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 5, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

FDA approves nivolumab plus cabozantinib for advanced renal cell carcinoma
Hematology / Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - January 22, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

U.S. Food and Drug Administration Approves Opdivo (nivolumab) in Combination with Cabometyx (cabozantinib) as First-line Treatment for Patients with Advanced Renal Cell Carcinoma
PRINCETON, N.J.--(BUSINESS WIRE) January 22, 2021-- Bristol Myers Squibb (NYSE: BMY) today announced that Opdivo (nivolumab) 240 mg (injection for intravenous use) every two weeks or 480 mg every four weeks in combination with Cabometyx... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - January 22, 2021 Category: Drugs & Pharmacology Source Type: news

Researchers uncover potentially promising therapeutic combination for renal cell carcinoma
(Beth Israel Deaconess Medical Center) Investigators have demonstrated that ACE2 expression is a good prognostic factor in RCC, that loss of ACE2 mediates resistance to classical treatments, and that in preclinical models, treatment with a drug that is downstream of ACE2 can improve tumor responses in RCC and significantly prolong survival. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 20, 2021 Category: Cancer & Oncology Source Type: news

Mitochondrial DNA alterations underlie an irreversible shift to aerobic glycolysis in fumarate hydratase-deficient renal cancer
Understanding the mechanisms of the Warburg shift to aerobic glycolysis is critical to defining the metabolic basis of cancer. Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) is an aggressive cancer characterized by biallelic inactivation of the gene encoding the Krebs cycle enzyme fumarate hydratase, an early shift to aerobic glycolysis, and rapid metastasis. We observed impairment of the mitochondrial respiratory chain in tumors from patients with HLRCC. Biochemical and transcriptomic analyses revealed that respiratory chain dysfunction in the tumors was due to loss of expression of mitochondrial DNA (mtDNA)&n...
Source: Signal Transduction Knowledge Environment - January 5, 2021 Category: Science Authors: Crooks, D. R., Maio, N., Lang, M., Ricketts, C. J., Vocke, C. D., Gurram, S., Turan, S., Kim, Y.-Y., Cawthon, G. M., Sohelian, F., De Val, N., Pfeiffer, R. M., Jailwala, P., Tandon, M., Tran, B., Fan, T. W.- M., Lane, A. N., Ried, T., Wangsa, D., Malayeri Tags: STKE Research Articles Source Type: news

Peninsula biotech Calithera cuts a third of jobs after kidney cancer trial flop
Calithera Biosciences Inc. shed nearly half of its value and will cut about 30 jobs after a mid-stage clinical trial of its marquee drug failed in kidney cancer patients. The South San Francisco company (NASDAQ: CALA) said the job cuts represent 35% of its workforce. The bulk of the job losses would be among those prepping for a potential commercial launch of the drug, called telaglenastat or CB-839. The company's 444-person Phase II study found that advanced or m etastatic renal cell carcinoma… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - January 4, 2021 Category: Biotechnology Authors: Ron Leuty Source Type: news

Peninsula biotech Calithera cuts a third of jobs after kidney cancer trial flop
Calithera Biosciences Inc. shed nearly half of its value and will cut about 30 jobs after a mid-stage clinical trial of its marquee drug failed in kidney cancer patients. The South San Francisco company (NASDAQ: CALA) said the job cuts represent 35% of its workforce. The bulk of the job losses would be among those prepping for a potential commercial launch of the drug, called telaglenastat or CB-839. The company's 444-person Phase II study found that advanced or m etastatic renal cell carcinoma… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - January 4, 2021 Category: American Health Authors: Ron Leuty Source Type: news